Advertisement
Technivie (ombitasvir

FDA Approves Technivie for Hepatitis C

0
For people with chronic hepatitis C genotype 4
In a new review

Review Highlights Surgical Options for Gallbladder Disease

0
Researchers outline pluses, minuses of various surgical approaches
Roux-en-Y gastric bypass is associated with attenuated markers of oxidative stress in subcutaneous adipose tissue

Improved Metabolic Profile After Roux-en-Y Gastric Bypass

0
A 3.5-fold AMPK activity increase and 50 percent drop in oxidative stress three months after surgery
Pharmacological thromboprophylaxis does not reduce the risk of venous thromboembolism in patients with cirrhosis

Pharmacological Prophylaxis Doesn’t Cut VTE in Cirrhosis

0
Low rate of VTE in hospitalized patients with cirrhosis; unaffected by pharmacological prophylaxis
Combination treatments show promise for HIV and hepatitis C virus coinfection

Combo Treatments Promising for HIV-HCV Coinfection

0
Sustained virologic response for ledipasvir and sofosbuvir; and for daclatasvir and sofosbuvir
First-degree relatives and spouses of those with celiac disease have increased risk for nonceliac autoimmune disease

Autoimmune Risk Up for Relatives of Those With Celiac Disease

0
Increased risk of nonceliac autoimmune disease for first-degree relatives, spouses of celiac patients
Americans are up to three times more likely to receive preventive care if they have health insurance

CDC: ACA May Have Boosted Uptake of Preventive Care

0
Insurance major factor in determining receipt of preventive services
Clinicians may be biased when it comes to the sexual orientation of patients

Clinicians May Harbor Biases About Sexual Orientation

0
Findings show need for sensitivity training, expert suggests
Strategies should be adopted to help with implementation of the Choosing Wisely program

Choosing Wisely: How to Implement in Clinical Practice

0
Strategies to improve chance of success include familiarization with evidence behind recs
For patients with systemic amyloidosis

Antibodies to Serum Amyloid P Deplete Amyloid Deposits

0
Phase 1 study shows safe, efficient depletion of deposits in liver, kidney in systemic amyloidosis